clinical trial · NCT07267130
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.·phase1·recruiting·n = 57
Chronic Obstructive Pulmonary DiseaseTQC3302 inhalation sprayTQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for InhalationTiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation sprayBudesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation sprayTQC3302 inhalation spray
brief summary
Groups 1, 3, 4, 5 and 6 of this research team adopted a single-center, open-label design. Group 2 used a three-sequence, three-period crossover design, where participants in this dose group were randomly assigned to the three sequences in a 1:1:1 ratio to undergo three-period crossover administration. Healthy adult subjects were selected to use TQC3302 inhalation spray to evaluate the safety, tolerability, and pharmacokinetic characteristics of single and multiple inhalations of TQC3302 inhalation spray in healthy participants.
started
Nov 25, 2025
primary completion
Oct 1, 2026
completion
Dec 1, 2026
last updated
Mar 10, 2026
official title
Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects in China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol